These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38179988)

  • 1. Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Franzone JP; Mackow NA; van Duin D
    Curr Opin Infect Dis; 2024 Apr; 37(2):137-143. PubMed ID: 38179988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections.
    El-Ghali A; Kunz Coyne AJ; Caniff K; Bleick C; Rybak MJ
    Pharmacotherapy; 2023 Jun; 43(6):502-513. PubMed ID: 37052117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
    Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D
    Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Karlowsky JA; Hackel MA; McLeod SM; Miller AA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0078122. PubMed ID: 36005804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections.
    Watkins RR; Bonomo RA
    Clin Infect Dis; 2023 May; 76(Suppl 2):S163-S165. PubMed ID: 37125465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant
    Petropoulou D; Siopi M; Vourli S; Pournaras S
    Front Cell Infect Microbiol; 2021; 11():814530. PubMed ID: 35127562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant
    August B; Matlob A; Kale-Pradhan PB
    Ann Pharmacother; 2024 Jul; 58(7):735-741. PubMed ID: 37817550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
    Dickstein Y; Lellouche J; Ben Dalak Amar M; Schwartz D; Nutman A; Daitch V; Yahav D; Leibovici L; Skiada A; Antoniadou A; Daikos GL; Andini R; Zampino R; Durante-Mangoni E; Mouton JW; Friberg LE; Dishon Benattar Y; Bitterman R; Neuberger A; Carmeli Y; Paul M;
    Clin Infect Dis; 2019 Aug; 69(5):769-776. PubMed ID: 30462182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ineffectiveness of colistin monotherapy in treating carbapenem-resistant Acinetobacter baumannii Pneumonia: A retrospective single-center cohort study.
    Jeon CH; Kim SH; Kim HT; Park KJ; Wi YM
    J Infect Public Health; 2024 May; 17(5):774-779. PubMed ID: 38518683
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
    Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.
    Shields RK; Paterson DL; Tamma PD
    Clin Infect Dis; 2023 May; 76(Suppl 2):S179-S193. PubMed ID: 37125467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Commentary: Uncertainty in Evaluating Treatment Outcomes in Carbapenem-Resistant Acinetobacter baumannii Infections.
    Howard-Anderson J; van Duin D
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0142421. PubMed ID: 34424045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea.
    Seok H; Choi WS; Lee S; Moon C; Park DW; Song JY; Cheong HJ; Kim J; Kim JY; Park MN; Kim YR; Lee HJ; Kim B; Pai H; Jo YM; Kim JH; Sohn JW
    J Glob Antimicrob Resist; 2021 Mar; 24():429-439. PubMed ID: 33571708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
    Katip W; Uitrakul S; Oberdorfer P
    Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.
    Seifert H; Müller C; Stefanik D; Higgins PG; Miller A; Kresken M
    J Antimicrob Chemother; 2020 Sep; 75(9):2616-2621. PubMed ID: 32516359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an
    Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting
    McLeod SM; O'Donnell JP; Narayanan N; Mills JP; Kaye KS
    Future Microbiol; 2024; 19(7):563-576. PubMed ID: 38426849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.
    Qureshi ZA; Hittle LE; O'Hara JA; Rivera JI; Syed A; Shields RK; Pasculle AW; Ernst RK; Doi Y
    Clin Infect Dis; 2015 May; 60(9):1295-303. PubMed ID: 25632010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.